

Press Release

New shareholder structure at Thommen Medical AG

Waldenburg, March 27, 2007

Thommen Medical AG announces that two groups of private investors have acquired the majority of the Company from venture capital investors. These two long term oriented investors have held an interest in Thommen Medical AG since its formation in 2001 and have over time increased their holding position.

Andreas Stutz, Thommen Medical's CEO welcomed the change in shareholding and commented "the venture capital investors actively supported and financed the Company in the start-up and expansion phase, and contributed substantially to the successful development of the Company. The private investors will over the long term continue the growth strategy and support the Company based on their business and industrial background".

Thommen Medical AG develops, produces and markets implants and surgical instruments for oral implantology. The Company headquartered in Waldenburg, Switzerland, was established in August 2001 by a dedicated and experienced team. Thommen Medical has established itself on the international market for implant dentistry very quickly and is setting new standards with the Swiss Precision Implant System (SPI[®]System). The Company was financed by a consortium of leading venture capital investors comprising HBM BioVentures, Invision Private Equity, VI Partners, BioMedInvest and NeoMed.

Thommen Medical has grown over the past couple of years with annual growth rates of around 65%, and has subsidiaries in Germany, Switzerland and the USA. In addition, the Company is represented by distributors in France, Italy, the Middle East, Japan and South Korea.

Contact:
Andreas Stutz, CEO

Thommen Medical AG
Hauptstrasse 26d
4437 Waldenburg, Schweiz

Tel. +41 (0)61 965 90 20
Fax +41 (0)61 965 90 21
E-Mail: info@thommenmedical.com
Internet: www.thommenmedical.com

About HBM BioVentures

HBM BioVentures invests in the human medicine, biotechnology and medical technology sectors worldwide. As a holding company it manages a mature, widely diversified portfolio of private and small-cap public companies. Investors appreciate HBM BioVentures as an integral part of their healthcare portfolio which gives them access to this newly created investment segment with its high value creation potential. HBM BioVentures is an active investor which finances, accompanies and supports portfolio companies as a key partner. With net assets of over CHF 1 billion, HBM BioVentures is one of the most liquid investments in this sector. Lean structures ensure a competitive cost structure, while wide-ranging expertise, operating industrial experience, highest professional standards and transparency distinguish the company. HBM BioVentures Ltd has a broad shareholder base. For further information please visit www.hmbioventures.com.

About Invision Private Equity

Invision Private Equity invests in innovative European growth companies and is focussed on the IT, telecommunications, medical technology and innovative services sectors. Invision has a long track record and experience from financing, developing and supporting more than 60 companies. To date, over 30 of these companies to date have been successfully sold or floated on a stock exchange. Invision currently holds assets of CHF 400 million and is investing typically between CHF 5 and 25 million in growth companies operating internationally.

For further Information please visit: www.invision.ch

About VI Partners

VI Partners is a Swiss venture capital firm that supports university spin-off's as well as other promising start-up companies with capital, coaching, consulting and networks. Via its current "Venture Incubator" fund VI Partners invests "Smart Money" to develop promising technology-based ideas for products and services into successful businesses. Venture Incubator was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ), and started operations in 2001. It now manages an investment fund of CHF 101 million. Its investors represent 10 blue-chip enterprises from industry and finance. For further information please visit:

www.vipartners.ch

About BioMedInvest

BioMedInvest AG is a healthcare-dedicated venture capital fund based in Switzerland, providing private equity financing to early- to mid-stage companies in Switzerland and neighbouring regions (Alpine Rim). BioMedInvest currently invests out of Fund I, which has a size of CHF 100 million and was closed in 2003. For further information please visit www.biomedinvest.ch.

About NeoMed

NeoMed Management is a Jersey domiciled venture capital firm, exclusively dedicated to investing in the healthcare and life science industry. Founded in 1996, NeoMed has established four funds, with total committed capital exceeding \$300 million. From offices in Oslo, Geneva and New York, NeoMed invests in innovative companies in the following industry sectors: pharmaceuticals, biotechnology, diagnostics, medical devices and instruments. Additional information:

www.neomed.net